Irwin MS, Naranjo A, Zhang FF, et al. Revised neuroblastoma risk classification system: a report from the Children’s Oncology Group. J Clin Oncol 2021;39:3229–3241.

• PubMed
Irwin MS, Naranjo A, Zhang FF, Revised neuroblastoma risk classification system: a report from the Children’s Oncology Group. J Clin Oncol 2021;39:3229–3241.)| false
• Search Google Scholar
• Export Citation

Bagatell R, Park JR, Acharya S, et al. NCCN Clinical Practice Guidelines in Oncology: Neuroblastoma. Version 1.2024. Accessed April 4, 2024. Available at: https://www.nccn.org

• PubMed
Bagatell R, Park JR, Acharya S, NCCN Clinical Practice Guidelines in Oncology: Neuroblastoma. Version 1.2024. Accessed April 4, 2024. Available at: https://www.nccn.org)| false
• Search Google Scholar
• Export Citation

Twist CJ, Schmidt ML, Naranjo A, et al. Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the Children’s Oncology Group Study ANBL0531. J Clin Oncol 2019;37:3243–3255.

• PubMed
Twist CJ, Schmidt ML, Naranjo A, Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the Children’s Oncology Group Study ANBL0531. J Clin Oncol 2019;37:3243–3255.)| false
• Search Google Scholar
• Export Citation

Bagatell R, DuBois SG, Naranjo A, et al. Children’s Oncology Group’s 2023 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2023;70(Suppl 6):e30572.

• PubMed
Bagatell R, DuBois SG, Naranjo A, Children’s Oncology Group’s 2023 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2023;70(Suppl 6):e30572.)| false
• Search Google Scholar
• Export Citation

Pinto N, Naranjo A, Hibbits E, et al. Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children’s Oncology Group (COG). Eur J Cancer 2019;112:66–79.

• PubMed
Pinto N, Naranjo A, Hibbits E, Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children’s Oncology Group (COG). Eur J Cancer 2019;112:66–79.)| false
• Search Google Scholar
• Export Citation

Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 2009;27:1007–1013.

• PubMed
Matthay KK, Reynolds CP, Seeger RC, Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 2009;27:1007–1013.)| false
• Search Google Scholar
• Export Citation

Berthold F, Ernst A, Hero B, et al. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. Br J Cancer 2018;119:282–290.

• PubMed
Berthold F, Ernst A, Hero B, Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. Br J Cancer 2018;119:282–290.)| false
• Search Google Scholar
• Export Citation

Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA 2019;322:746–755.

• PubMed
Park JR, Kreissman SG, London WB, Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA 2019;322:746–755.)| false
• Search Google Scholar
• Export Citation

Mody R, Yu AL, Naranjo A, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. J Clin Oncol 2020;38:2160–2169.

• PubMed
Mody R, Yu AL, Naranjo A, Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. J Clin Oncol 2020;38:2160–2169.)| false
• Search Google Scholar
• Export Citation

Goldsmith KC, Park JR, Kayser K, et al. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med 2023;29:1092–1102.

• PubMed
Goldsmith KC, Park JR, Kayser K, Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med 2023;29:1092–1102.)| false
• Search Google Scholar
• Export Citation

DuBois SG, Granger MM, Groshen S, et al. Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: a report from NANT Consortium. J Clin Oncol 2021;39:3506–3514.

• PubMed
DuBois SG, Granger MM, Groshen S, Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: a report from NANT Consortium. J Clin Oncol 2021;39:3506–3514.)| false
• Search Google Scholar
• Export Citation

Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054–1060.

• PubMed
Matthay KK, Yanik G, Messina J, Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054–1060.)| false
• Search Google Scholar
• Export Citation

Oesterheld J, Ferguson W, Karveka JM, et al. Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. J Clin Oncol 2024;42:90–102.

• PubMed
Oesterheld J, Ferguson W, Karveka JM, Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. J Clin Oncol 2024;42:90–102.)| false
• Search Google Scholar
• Export Citation